ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 047,92
-1,85%
Dow Jones
42 520,99
-1,55%
DAX
22 326,81
-3,51%
Brent Oil
71,035
-0,51%
Bitcoin
87 618,11
1,78%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Apellis Pharmaceuticals Inc (APLS)

  7. Apellis Pharmaceuticals Inc (APLS) Actualités

APLS

Apellis Pharmaceuticals (APLS)

Apellis Pharmaceuticals Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:APLS
DateHeureSourceTitreSymboleSociété
28/02/202513h22Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:APLSApellis Pharmaceuticals Inc
28/02/202513h05GlobeNewswire Inc.Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial ResultsNASDAQ:APLSApellis Pharmaceuticals Inc
24/02/202513h00GlobeNewswire Inc.Apellis Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care ConferenceNASDAQ:APLSApellis Pharmaceuticals Inc
20/02/202508h00GlobeNewswire Inc.Apellis and Sobi Announce EMA Validation of Indication Extension Application for Aspaveli® (pegcetacoplan) for C3G and Primary IC-MPGNNASDAQ:APLSApellis Pharmaceuticals Inc
14/02/202513h00GlobeNewswire Inc.Apellis Pharmaceuticals to Host Conference Call on February 28, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial ResultsNASDAQ:APLSApellis Pharmaceuticals Inc
12/02/202519h59Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:APLSApellis Pharmaceuticals Inc
11/02/202521h13Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:APLSApellis Pharmaceuticals Inc
04/02/202522h05GlobeNewswire Inc.Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:APLSApellis Pharmaceuticals Inc
27/01/202522h00GlobeNewswire Inc.Apellis Receives Approval of SYFOVRE® (pegcetacoplan) in Australia for Geographic Atrophy (GA)NASDAQ:APLSApellis Pharmaceuticals Inc
13/01/202515h08Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:APLSApellis Pharmaceuticals Inc
13/01/202515h00GlobeNewswire Inc.Apellis Highlights Commercial Growth and Strategic Priorities at 43rd Annual J.P. Morgan Healthcare ConferenceNASDAQ:APLSApellis Pharmaceuticals Inc
10/01/202523h38Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:APLSApellis Pharmaceuticals Inc
10/01/202513h00GlobeNewswire Inc.Apellis Announces Keli Walbert to Join the Board of DirectorsNASDAQ:APLSApellis Pharmaceuticals Inc
06/01/202513h00GlobeNewswire Inc.Apellis Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceNASDAQ:APLSApellis Pharmaceuticals Inc
27/11/202413h00GlobeNewswire Inc.Apellis Pharmaceuticals to Present at Upcoming Investor ConferencesNASDAQ:APLSApellis Pharmaceuticals Inc
22/11/202422h16Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:APLSApellis Pharmaceuticals Inc
22/11/202414h47Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:APLSApellis Pharmaceuticals Inc
12/11/202413h00GlobeNewswire Inc.Apellis Pharmaceuticals to Host a Fireside Chat at the Jefferies London Healthcare ConferenceNASDAQ:APLSApellis Pharmaceuticals Inc
05/11/202413h05GlobeNewswire Inc.Apellis Pharmaceuticals Reports Third Quarter 2024 Financial ResultsNASDAQ:APLSApellis Pharmaceuticals Inc
05/11/202412h57Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:APLSApellis Pharmaceuticals Inc
05/11/202412h46IH Market NewsU.S. Index Futures Rise as Election Looms; Oil and Gold Prices SteadyNASDAQ:APLSApellis Pharmaceuticals Inc
26/10/202420h00GlobeNewswire Inc.Pivotal VALIANT Results Presented at Kidney Week Highlight Strength of Pegcetacoplan Treatment Effect in Patients with C3G / Primary IC-MPGNNASDAQ:APLSApellis Pharmaceuticals Inc
22/10/202413h00GlobeNewswire Inc.Apellis Pharmaceuticals to Host Conference Call on November 5, 2024, to Discuss Third Quarter 2024 Financial ResultsNASDAQ:APLSApellis Pharmaceuticals Inc
16/10/202413h00GlobeNewswire Inc.Apellis Announces Oral Presentation at American Society of Nephrology (ASN) Kidney Week on Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGNNASDAQ:APLSApellis Pharmaceuticals Inc
25/09/202413h00GlobeNewswire Inc.Apellis Pharmaceuticals to Host a Fireside Chat at the UBS Virtual Ophthalmology DayNASDAQ:APLSApellis Pharmaceuticals Inc
20/09/202411h00GlobeNewswire Inc.Apellis Receives Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy (GA) in the EU Following Re-ExaminationNASDAQ:APLSApellis Pharmaceuticals Inc
08/08/202413h32PR Newswire (US)Sobi and Apellis announce positive topline results from phase 3 VALIANT study of pegcetacoplan in C3G and primary IC-MPGNNASDAQ:APLSApellis Pharmaceuticals Inc
08/08/202413h00GlobeNewswire Inc.Apellis and Sobi Announce Positive Topline Results from Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGNNASDAQ:APLSApellis Pharmaceuticals Inc
01/08/202413h05GlobeNewswire Inc.Apellis Pharmaceuticals Reports Second Quarter 2024 Financial ResultsNASDAQ:APLSApellis Pharmaceuticals Inc
19/07/202401h39PR Newswire (US)Kuehn Law Encourages Investors of Apellis Pharmaceuticals, Inc. to Contact Law FirmNASDAQ:APLSApellis Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:APLS

Dernières Valeurs Consultées

BOV
COIN11
Buena Vista Neos Bitcoin...
BOV
D1OM34R
Dominion Energy
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés

Supprimer les publicités

Inscrivez-vous pour une expérience sans publicité

Aucune publicité

Essayez maintenant

Conserver les annonces